How is industry responding to the covid-19 pandemic?
During the covid-19 pandemic, it is even more important that we connect, share information and help each other meet the unique challenges faced by our industry. The Senior BioPhorum Connect group – consisting of the le...
Interested in being a BioPhorum peer reviewer?
Excellence has always been at the heart of everything we do – from holding face-to-face meetings to publishing technic...
How to learn about PUPSIT in terminal sterilizing filtration – the science, implications and implementation
How to learn about PUPSIT in terminal sterilizing filtration – the science, implications and implementation Pre-use po...
BioPhorum CGT – delivering and shaping industry approaches
Cell and gene therapies (CGT) are changing the treatment landscape for many diseases and, with each new headline, patien...
Mapping cell and gene therapy manufacturing
Cell and gene therapy (CGT) is a diverse field, with products and processes as varied as the patients it is trying to tr...
IT for Cell and Gene Therapy
In 2020 only a few cell and gene therapies (CGT) are approved for commercial use, but hundreds of clinical trials are un...
Current mission of the High-Level Analytics Workstream
The High-Level Analytics Workstream has been running since September 2018, with representatives from 21 member companies...
CGT Environmental Health and Safety (EHS) and BioSafety workstream
Running since September 2018, the EHS and BioSafety Workstream has representatives from 15 member companies. The 23 subj...
BioPhorum accelerates growth
We are delighted that BioPhorum has been ranked in the fourth annual list of FT 1000 Europe’s Fastest Growing Compani...
As Ask BPOG morphs into Ask BioPhorum, are you asking enough questions of the community?
Since 2013, Ask BPOG has become a great asset for the industry, with more than 3,000 questions being posted and 11,000 r...
How the fast-start C> Phorum is delivering results
From a standing start in 2018, the BioPhorum Cell & Gene Therapy (C>) Phorum has made huge progress on a range of init...
Driving progress in Cell & Gene Therapy
Now with 19 member companies and 183 subject matter experts, the BioPhorum Cell & Gene Therapy (C>) Phorum has...
Cell and Gene Therapy Phorum accelerates progress
The BioPhorum Cell & Gene Therapy Phorum has made significant progress since its creation in 2018 – from building netw...
How is industry responding to the covid-19 pandemic?
During the covid-19 pandemic, it is even more important that we connect, share information and help each other meet the ...
Interested in being a BioPhorum peer reviewer?
Excellence has always been at the heart of everything we do – from holding face-to-face meetings to publishing technic...
How to learn about PUPSIT in terminal sterilizing filtration – the science, implications and implementation
How to learn about PUPSIT in terminal sterilizing filtration – the science, implications and implementation Pre-use po...
BioPhorum CGT – delivering and shaping industry approaches
Cell and gene therapies (CGT) are changing the treatment landscape for many diseases and, with each new headline, patien...
Mapping cell and gene therapy manufacturing
Cell and gene therapy (CGT) is a diverse field, with products and processes as varied as the patients it is trying to tr...
IT for Cell and Gene Therapy
In 2020 only a few cell and gene therapies (CGT) are approved for commercial use, but hundreds of clinical trials are un...
Current mission of the High-Level Analytics Workstream
The High-Level Analytics Workstream has been running since September 2018, with representatives from 21 member companies...
CGT Environmental Health and Safety (EHS) and BioSafety workstream
Running since September 2018, the EHS and BioSafety Workstream has representatives from 15 member companies. The 23 subj...
BioPhorum accelerates growth
We are delighted that BioPhorum has been ranked in the fourth annual list of FT 1000 Europe’s Fastest Growing Compani...
As Ask BPOG morphs into Ask BioPhorum, are you asking enough questions of the community?
Since 2013, Ask BPOG has become a great asset for the industry, with more than 3,000 questions being posted and 11,000 r...
How the fast-start C> Phorum is delivering results
From a standing start in 2018, the BioPhorum Cell & Gene Therapy (C>) Phorum has made huge progress on a range of init...
Driving progress in Cell & Gene Therapy
Now with 19 member companies and 183 subject matter experts, the BioPhorum Cell & Gene Therapy (C>) Phorum has...
